Jack W Hsu

Jack W Hsu, M.D.

Associate Professor

Department: MD-HEMATOLOGY/ONCOLOGY
Business Phone: (352) 273-7832
Business Email: hsujw@ufl.edu

About Jack W Hsu

Jack Hsu, MD, is a clinical professor of medicine within the division of hematology and oncology, and is an integral member of the Bone Marrow Transplant Unit.

Teaching Profile

Courses Taught
2018
MDC7200 Medicine Clerkship
2021
PAS5010 Intro to Medicine 1

Clinical Profile

Subspecialties
  • Hematology and Oncology
Areas of Interest
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia – adult
  • Bone marrow transplant
  • Bone tumor
  • Cancer – resources
  • Graft-versus-host disease
  • Leukemia
  • Leukemia – resources
  • Lymphoma – Overview
  • Non-Hodgkin lymphoma
  • Stem cell research

Publications

2022
The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor’s Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials.
Transplantation and cellular therapy. [DOI] 10.1016/j.jtct.2022.05.042. [PMID] 35688325.
2021
Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial.
Frontiers in immunology. [DOI] 10.3389/fimmu.2021.700045. [PMID] 34539628.
2021
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. [DOI] 10.1200/JCO.20.01739. [PMID] 34156898.
2021
Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations.
Transplantation and cellular therapy. [DOI] 10.1016/j.jtct.2021.03.008. [PMID] 33823169.
2021
The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic.
Transplantation and cellular therapy. [DOI] 10.1016/j.jtct.2021.03.015. [PMID] 33865804.
2020
Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2020.02.011. [PMID] 32088366.
2020
Dietary Intake and Diet Quality of Hematopoietic Stem Cell Transplantation Survivors.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2020.02.017. [PMID] 32105830.
2020
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2019.10.017. [PMID] 31669399.
2020
Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
British journal of haematology. [DOI] 10.1111/bjh.16629. [PMID] 32236943.
2020
Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.
Leukemia & lymphoma. [DOI] 10.1080/10428194.2020.1783444. [PMID] 32662346.
2020
Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield.
Blood advances. [DOI] 10.1182/bloodadvances.2019000923. [PMID] 32092138.
2019
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Blood advances. [DOI] 10.1182/bloodadvances.2018028316. [PMID] 31208955.
2019
Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients.
Bone marrow transplantation. [DOI] 10.1038/s41409-018-0240-3. [PMID] 29884851.
2018
Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Mycoses. [DOI] 10.1111/myc.12748. [PMID] 29364548.
2018
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Blood advances. [DOI] 10.1182/bloodadvances.2018024844. [PMID] 30396912.
2018
Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
Journal of clinical apheresis. [DOI] 10.1002/jca.21556. [PMID] 28556233.
2017
A rare case of Raoultella planticola urinary tract infection in an immunocompromised patient with multiple myeloma.
IDCases. [DOI] 10.1016/j.idcr.2017.02.002. [PMID] 28271042.
2017
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2017.01.078. [PMID] 28115276.
2017
Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
Blood cancer journal. [DOI] 10.1038/s41408-017-0007-x. [PMID] 29176662.
2016
A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.
Leukemia research. [DOI] 10.1016/j.leukres.2016.04.013. [PMID] 27132034.
2016
Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.
Blood. [DOI] 10.1182/blood-2015-08-664706. [PMID] 27297790.
2016
Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
Clinical transplantation. [DOI] 10.1111/ctr.12762. [PMID] 27219740.
2016
Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2016.05.007. [PMID] 27184625.
2015
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2014.10.021. [PMID] 25445023.
2015
Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2014.10.006. [PMID] 25316109.
2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. [DOI] 10.1200/JCO.2015.62.7273. [PMID] 26527780.
2015
Poor Peripheral Blood Stem Cell Mobilization Correlates With Worse Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Biology of Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2014.11.175.
2015
Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2014.10.007. [PMID] 25316111.
2015
Uric acid and the prediction models of tumor lysis syndrome in AML.
PloS one. [DOI] 10.1371/journal.pone.0119497. [PMID] 25775138.
2014
Advances in the management of viral infections.
Cancer treatment and research. [DOI] 10.1007/978-3-319-04220-6_5. [PMID] 24706224.
2014
ALK1 as a novel therapeutic target for CD30⁺ T-anaplastic large cell lymphoma.
Journal of the National Cancer Institute. [DOI] 10.1093/jnci/djt454. [PMID] 24491304.
2014
Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2014.03.013. [PMID] 24641829.
2014
Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2013.12.567. [PMID] 24388803.
2014
Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2013.11.032. [PMID] 24321745.
2014
Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2014.06.036. [PMID] 25008330.
2014
Elevated incidence of chronic myeloid leukaemia in immunosuppressed solid organ transplant recipients.
British journal of haematology. [DOI] 10.1111/bjh.12885. [PMID] 24697357.
2014
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. [DOI] 10.1200/JCO.2014.55.2018. [PMID] 25154823.
2014
Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2014.03.014. [PMID] 24641828.
2014
Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2014.05.020. [PMID] 24880021.
2014
Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2014.07.009. [PMID] 25042734.
2014
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.
Blood. [DOI] 10.1182/blood-2014-04-567164. [PMID] 24982504.
2014
Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II Study.
Clinical Medicine Insights. Oncology. [DOI] 10.4137/CMO.S16835. [PMID] 25232286.
2013
Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2013.01.009. [PMID] 23333532.
2013
Association of Mannose Binding Lectin (Mbl) Levels and Invasive Fungal Disease (Ifd) in Hematologic Malignancy Patients Undergoing Hematopoietic Stem Cell Transplantation (Hsct) Or Receiving Chemotherapy
Biology of Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2012.11.274.
2013
Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2012.11.016. [PMID] 23200705.
2013
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. [DOI] 10.1200/JCO.2012.46.0188. [PMID] 23897963.
2013
Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2013.01.024. [PMID] 23380340.
2013
The role of monoclonal antibodies in the treatment of lymphomas.
Expert opinion on biological therapy. [DOI] 10.1517/14712598.2012.755172. [PMID] 23265087.
2012
A Phase I Study of the Vascular Disrupting Combretastatin, Oxi4503, in Patients With Relapsed and Refractory Acute Myeloid Leukemia (Aml) and Myelodysplastic Syndromes (Mds)
Blood.
2012
A Phase II Study of Allogeneic Transplantation for Older Patients With Aml in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From Calgb 100103/Bmt Ctn 0502
Blood.
2012
Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2011.11.026. [PMID] 22155506.
2012
Higher Than Expected Incidence of Chronic Myeloid Leukemia in Solid Organ Transplant Recipients.
Blood.
2012
Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2012.06.018. [PMID] 22863842.
2012
Peripheral Blood Cd34(+) Specific Donor Chimerism Analysis as An Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients With Myelodysplastic Syndromes and Acute Myelogenous Leukemia.
Blood.
2012
Quality of life, social challenges, and psychosocial support for long-term survivors after allogeneic hematopoietic stem-cell transplantation.
Seminars in hematology. [DOI] 10.1053/j.seminhematol.2011.10.004. [PMID] 22221790.
2012
Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: a Single Center Prospective Phase II Study- An Update
Blood.
2011
A 21-year-old woman with blastic NK cell leukemia/lymphoma who achieved durable remission with HyperCVAD and unrelated umbilical cord blood transplant.
Clinical advances in hematology & oncology : H&O. [PMID] 22402467.
2011
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2010.06.018. [PMID] 20601033.
2011
Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology.
Hematology/oncology clinics of North America. [DOI] 10.1016/j.hoc.2010.11.008. [PMID] 21236393.
2011
Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients.
Advances in hematology. [DOI] 10.1155/2011/517561. [PMID] 22190942.
2011
Stress and abdominal fat: preliminary evidence of moderation by the cortisol awakening response in Hispanic peripubertal girls.
Obesity (Silver Spring, Md.). [DOI] 10.1038/oby.2010.287. [PMID] 21127479.
2010
Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology.
Infectious disease clinics of North America. [DOI] 10.1016/j.idc.2010.01.010. [PMID] 20466269.
2010
Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes.
Clinical advances in hematology & oncology : H&O. [PMID] 20351682.
2009
Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant.
American journal of hematology. [DOI] 10.1002/ajh.21449. [PMID] 19536846.
2008
Non-Myeloablative Allogeneic Stem Cell Transplantation To Treat High Risk Heavily Pretreated Multiple
Biology of Blood and Marrow Transplantation. [DOI] 10.1016/j.bbmt.2007.12.198.
2006
Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. [PMID] 17084373.
2005
Malignant parotid tumors: presentation, clinical/pathologic prognostic factors, and treatment outcomes.
International journal of radiation oncology, biology, physics. [PMID] 15629601.
2003
Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy.
Blood. [PMID] 12509385.
2002
Parvovirus b19-associated pure red cell aplasia in chronic graft-versus-host disease.
British journal of haematology. [PMID] 12358943.

Grants

Jul 2021 ACTIVE
A Phase I/II open label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of ONO-7475 in patients with acute leukemias or myelodysplastic syndromes
Role: Principal Investigator
Funding: MEDPACE via ONO PHARMACEUTICAL
Mar 2021 ACTIVE
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC 412) (IND #101261) or Placebo in Newly Diagnosed Patients <60 Years of Age with FLT3 Mutated A
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Sep 2018 ACTIVE
Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects Less than or Equal to 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
Role: Principal Investigator
Funding: AROG PHARMACEUTICALS
Mar 2018 – Feb 2022
Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects with Acute Myeloid Leukemia (AML) that is Refractory to or Relapsed after Standard Induction Therapy.
Role: Principal Investigator
Funding: MOLECULIN BIOTECH
Oct 2016 – Oct 2021
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission
Role: Principal Investigator
Funding: ASTELLAS PHARMA US, INC
Jul 2016 ACTIVE
A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Role: Principal Investigator
Funding: DAIICHI SANKYO
Feb 2016 – Feb 2021
Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
Role: Principal Investigator
Funding: ASTELLAS PHARMA US, INC
Aug 2015 – Aug 2020
AN OPEN-LABEL PHASE 2 PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY OF CLT-008 MYELOID PROGENITOR CELLS AS A SUPPORTIVE CARE MEASURE DURING INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA
Role: Principal Investigator
Funding: SYNTERACT via CELLERANT THERAPEUTICS
Oct 2013 – Oct 2017
An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigators Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC via PFIZER INC
Sep 2013 – Sep 2020
A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Role: Principal Investigator
Funding: SOUTHWEST ONCOLOGY GROUP via NATL INST OF HLTH NCI
Jul 2012 – Aug 2019
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance
Role: Principal Investigator
Funding: EASTERN COOP ONCOLOGY GROUP via NATL INST OF HLTH NCI
Feb 2011 – Feb 2017
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
Role: Principal Investigator
Funding: GENZYME CORP
Feb 2011 – Feb 2017
CLINICAL AND ECONOMIC IMPACT OF UPFRONT PLERIXAFOR IN AUTOLOGOUS TRANSPLANTATION
Role: Principal Investigator
Funding: GENZYME CORP
Apr 2009 – Jul 2019
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin / Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC 412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated A
Role: Principal Investigator
Funding: EASTERN COOP ONCOLOGY GROUP via NATL INST OF HLTH
Jul 2002 – Sep 2020
94101912
Role: Principal Investigator
Funding: EASTERN COOP ONCOLOGY GROUP via NATL INST OF HLTH

Contact Details

Phones:
Business:
(352) 273-7832
Emails:
Business:
hsujw@ufl.edu
Addresses:
Business Mailing:
PO Box 100277
GAINESVILLE FL 32610